Should I buy or sell CONMED stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CNMD shares. View CNMD analyst ratings or view top-rated stocks .

What is CONMED's stock price target for 2024?

6 equities research analysts have issued 1-year price objectives for CONMED's shares. Their CNMD share price targets range from $107.00 to $141.00. On average, they predict the company's stock price to reach $126.17 in the next twelve months. This suggests a possible upside of 15.1% from the stock's current price. View analysts price targets for CNMD or view top-rated stocks among Wall Street analysts .

How have CNMD shares performed in 2023?

CONMED's stock was trading at $88.64 at the beginning of the year. Since then, CNMD shares have increased by 23.7% and is now trading at $109.62. View the best growth stocks for 2023 here .

Are investors shorting CONMED?

CONMED saw a increase in short interest in November. As of November 15th, there was short interest totaling 4,720,000 shares, an increase of 7.8% from the October 31st total of 4,380,000 shares. Based on an average trading volume of 359,400 shares, the short-interest ratio is presently 13.1 days. View CONMED's Short Interest .

When is CONMED's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 1st 2024. View our CNMD earnings forecast .

How were CONMED's earnings last quarter?

CONMED Co. (NYSE:CNMD) posted its quarterly earnings data on Wednesday, October, 25th. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.07. The company earned $304.58 million during the quarter, compared to analysts' expectations of $301.22 million. CONMED had a trailing twelve-month return on equity of 11.46% and a net margin of 4.96%.

How often does CONMED pay dividends? What is the dividend yield for CONMED?

CONMED declared a quarterly dividend on Thursday, August 10th. Stockholders of record on Friday, September 15th will be paid a dividend of $0.20 per share on Thursday, October 5th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.73%. The ex-dividend date is Thursday, September 14th. Read our dividend analysis for CNMD .

Is CONMED a good dividend stock?

CONMED (NYSE:CNMD) pays an annual dividend of $0.80 per share and currently has a dividend yield of 0.75%. The dividend payout ratio is 43.24%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CNMD will have a dividend payout ratio of 18.10% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for CNMD .

What ETFs hold CONMED's stock?

ETFs with the largest weight of CONMED (NYSE:CNMD) stock in their portfolio include Small Cap US Equity Select ETF (RNSC) , Invesco S&P SmallCap Health Care ETF (PSCH) , SPDR S&P Health Care Equipment ETF (XHE) , Xtrackers S&P SmallCap 600 ESG ETF (SMLE) , SPDR S&P SmallCap 600 ESG ETF (ESIX) , SPDR S&P 600 Small Cap ETF (SLY) , Vanguard S&P Small-Cap 600 Value ETF (VIOV) and Vanguard S&P Small-Cap 600 ETF (VIOO) .

What guidance has CONMED issued on next quarter's earnings?

CONMED issued an update on its FY23 earnings guidance on Wednesday, October, 25th. The company provided EPS guidance of $3.45-3.55 for the period, compared to the consensus EPS estimate of $3.48. The company issued revenue guidance of $1.24-1.26 billion, compared to the consensus revenue estimate of $1.25 billion.

Who are CONMED's major shareholders?

CONMED's stock is owned by a variety of retail and institutional investors. Top institutional investors include Earnest Partners LLC (7.37%), Loomis Sayles & Co. L P (2.57%), Principal Financial Group Inc. (1.99%), Bank of New York Mellon Corp (1.39%), Jennison Associates LLC (1.19%) and Northern Trust Corp (1.10%). Insiders that own company stock include Brian Concannon , Curt R Hartman , Daniel S Jonas , John D Ferrell, Johonna Marie Pelletier, Peter K Shagory , Stanley W Peters III , Todd W Garner and Todd W Garner . View institutional ownership trends .

How do I buy shares of CONMED?

Shares of CNMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

CONMED Stock Price, News & Analysis (NYSE:CNMD)

$109.62

+2.35 (+2.19%)

(As of 12/1/2023 ET)

Compare

Today's Range: $106.93
▼
$109.92
50-Day Range: $91.30
▼
$109.62
52-Week Range: $82.97
▼
$138.47

Volume: 225,600 shs
Average Volume: 303,635 shs
Market Capitalization: $3.37 billion

P/E Ratio: 59.25
Dividend Yield: 0.73%
Price Target: $126.17

CONMED MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 15.1% Upside
$126.17 Price Target
Short Interest: Bearish
15.35% of Shares Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: -0.74
Upright™ Environmental Score
News Sentiment: -0.50
Based on 2 Articles This Week
Insider Trading: Selling Shares
$337,488 Sold Last Quarter
Proj. Earnings Growth: 26.29%
From $3.50 to $4.42 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

415th out of 952 stocks

Electromedical Equipment Industry

8th out of 22 stocks

2.4

Analyst's Opinion

Consensus Rating
CONMED has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $126.17, CONMED has a forecasted upside of 15.1% from its current price of $109.62.
Amount of Analyst Coverage
CONMED has only been the subject of 4 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
15.35% of the outstanding shares of CONMED have been sold short.
Short Interest Ratio / Days to Cover
CONMED has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.
Change versus previous month
Short interest in CONMED has recently increased by 7.76%, indicating that investor sentiment is decreasing significantly.

1.7

Dividend Strength

Dividend Yield
CONMED has a dividend yield of 0.75%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
CONMED does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of CONMED is 43.24%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, CONMED will have a dividend payout ratio of 18.10% next year. This indicates that CONMED will be able to sustain or increase its dividend.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
CONMED has received a 64.86% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Surgical instruments", "Medical technology engineering", and "Training for medical professionals" products. See details.
Environmental Sustainability
The Environmental Impact score for CONMED is -0.74.

1.4

News and Social Media Coverage

News Sentiment
CONMED has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for CONMED this week, compared to 3 articles on an average week.
MarketBeat Follows
2 people have added CONMED to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CONMED insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $337,488.00 in company stock.
Percentage Held by Insiders
Only 7.60% of the stock of CONMED is held by insiders.

3.1

Earnings and Valuation

Earnings Growth
Earnings for CONMED are expected to grow by 26.29% in the coming year, from $3.50 to $4.42 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CONMED is 59.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 110.44.
Price to Earnings Ratio vs. Sector
The P/E ratio of CONMED is 59.25, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 86.19.
Price to Earnings Growth Ratio
CONMED has a PEG Ratio of 1.07. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
CONMED has a P/B Ratio of 4.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About CONMED Stock (NYSE:CNMD)

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

CNMD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CNMD Stock News Headlines

November 28, 2023 | americanbankingnews.com

Analyzing CONMED (NYSE:CNMD) and NeurAxis (NASDAQ:NRXS)

November 24, 2023 | finance.yahoo.com

Conmed (CNMD) Up 14.3% Since Last Earnings Report: Can It Continue?

December 2, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 24, 2023 | americanbankingnews.com

CONMED Co. (NYSE:CNMD) Given Average Rating of "Moderate Buy" by Analysts

November 22, 2023 | finance.yahoo.com

Is There An Opportunity With CONMED Corporation's (NYSE:CNMD) 44% Undervaluation?

November 13, 2023 | finance.yahoo.com

CONMED Corporation to Participate in a Fireside Chat at the Piper Sandler Healthcare Conference

October 31, 2023 | finance.yahoo.com

CONMED Corporation to Participate in Fireside Chats at Two Investor Conferences on November 14-15

October 30, 2023 | finance.yahoo.com

The Conmed Corp (CNMD) Company: A Short SWOT Analysis

December 2, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

October 28, 2023 | seekingalpha.com

Conmed: Sector Derating And A New Competitive Threat Shouldn't Overshadow A Solid Core Business

October 27, 2023 | msn.com

Piper Sandler Maintains Conmed (CNMD) Overweight Recommendation

October 27, 2023 | finance.yahoo.com

CONMED Corporation (NYSE:CNMD) Q3 2023 Earnings Call Transcript

October 27, 2023 | markets.businessinsider.com

Hold Rating on Conmed: Balancing Double-Digit Revenue Growth and Market Challenges

October 27, 2023 | nasdaq.com

Stifel Maintains Conmed (CNMD) Buy Recommendation

October 27, 2023 | nasdaq.com

Needham Maintains Conmed (CNMD) Buy Recommendation

October 26, 2023 | markets.businessinsider.com

Hold Rating on Conmed Amid Strong Q3 Performance and Anticipated Supply Constraints

October 26, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Conmed (CNMD), Edwards Lifesciences (EW) and Prothena (PRTA)

October 26, 2023 | finance.yahoo.com

CNMD or ALGN: Which Is the Better Value Stock Right Now?

October 25, 2023 | markets.businessinsider.com

Conmed Corp. Q3 Profit Decreases, but beats estimates

October 25, 2023 | finance.yahoo.com

Conmed (CNMD) Reports Q3 Earnings: What Key Metrics Have to Say

October 25, 2023 | sfgate.com

Conmed: Q3 Earnings Snapshot

October 25, 2023 | finance.yahoo.com

CONMED Corporation Announces Third Quarter 2023 Financial Results

October 25, 2023 | finance.yahoo.com

Conmed Corp (CNMD) Announces Q3 2023 Financial Results

October 25, 2023 | seekingalpha.com

CONMED Corporation 2023 Q3 - Results - Earnings Call Presentation

October 19, 2023 | finance.yahoo.com

Are Medical Stocks Lagging Anebulo Pharmaceuticals (ANEB) This Year?

October 9, 2023 | finance.yahoo.com

Those who invested in CONMED (NYSE:CNMD) five years ago are up 40%

October 4, 2023 | finance.yahoo.com

CONMED Corporation to Announce Third Quarter 2023 Financial Results on October 25, 2023

See More Headlines

Receive CNMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CONMED and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 10/5 Dividend: 9/14/2023
Dividend Payable: 10/05/2023
Last Earnings: 10/25/2023
Today: 12/01/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/01/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Electromedical equipment
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:CNMD
CUSIP: N/A
CIK: 816956
Web: www.conmed.com
Phone: (727) 392-6464
Fax: 315-797-0321
Employees: 4,100
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $126.17
High Stock Price Target: $141.00
Low Stock Price Target: $107.00
Potential Upside/Downside: +15.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.85
Trailing P/E Ratio: 59.25
Forward P/E Ratio: 31.32
P/E Growth: 1.06
Net Income: $-80,580,000.00
Net Margins: 4.96%
Pretax Margin: 2.53%
Return on Equity: 11.46%
Return on Assets: 3.80%

Debt

Debt-to-Equity Ratio: 1.18
Current Ratio: 1.66
Quick Ratio: 0.80

Sales & Book Value

Annual Sales: $1.05 billion
Price / Sales: 3.22
Cash Flow: $5.39 per share
Price / Cash Flow: 20.32
Book Value: $25.89 per share
Price / Book: 4.23

Miscellaneous

Outstanding Shares: 30,750,000
Free Float: 28,415,000
Market Cap: $3.37 billion
Optionable: Optionable
Beta: 1.37

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. Curt R. Hartman (Age 59)
Chairman of the Board, CEO & President
Comp: $1.5M
Mr. Todd W. Garner (Age 54)
Executive VP & CFO
Comp: $783.48k
Ms. Heather L. Cohen (Age 50)
Executive VP and Chief Human Resources & Legal Officer
Comp: $561.01k
Mr. Patrick J. Beyer (Age 57)
President of International & Global Orthopedics
Comp: $1.22M
Mr. Stanley W. Peters III (Age 48)
President of Advanced Surgical & Advanced Endoscopic Technologies
Comp: $648.12k
Mr. Peter K. Shagory (Age 54)
Executive Vice President of Strategy & Corporate Development
Ms. Shanna L. Cotti-Osmanski (Age 46)
Executive VP of Information Technology & CIO
Mr. Brent Lalomia (Age 48)
Executive Vice President of Quality Assurance & Regulatory Affairs
Mr. John Ferrell (Age 55)
Executive Vice President of Human Resources
Mr. Daniel S. Jonas Esq. (Age 59)
Special Counsel & Corporate Secretary
Comp: $646.48k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CNMD Stock Analysis - Frequently Asked Questions

Should I buy or sell CONMED stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CNMD shares.
View CNMD analyst ratings or view top-rated stocks.
What is CONMED's stock price target for 2024?: 6 equities research analysts have issued 1-year price objectives for CONMED's shares. Their CNMD share price targets range from $107.00 to $141.00. On average, they predict the company's stock price to reach $126.17 in the next twelve months. This suggests a possible upside of 15.1% from the stock's current price.
View analysts price targets for CNMD or view top-rated stocks among Wall Street analysts.
How have CNMD shares performed in 2023?: CONMED's stock was trading at $88.64 at the beginning of the year. Since then, CNMD shares have increased by 23.7% and is now trading at $109.62.
View the best growth stocks for 2023 here.
Are investors shorting CONMED?: CONMED saw a increase in short interest in November. As of November 15th, there was short interest totaling 4,720,000 shares, an increase of 7.8% from the October 31st total of 4,380,000 shares. Based on an average trading volume of 359,400 shares, the short-interest ratio is presently 13.1 days.
View CONMED's Short Interest.
When is CONMED's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 1st 2024.
View our CNMD earnings forecast.
How were CONMED's earnings last quarter?: CONMED Co. (NYSE:CNMD) posted its quarterly earnings data on Wednesday, October, 25th. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.07. The company earned $304.58 million during the quarter, compared to analysts' expectations of $301.22 million. CONMED had a trailing twelve-month return on equity of 11.46% and a net margin of 4.96%.

How often does CONMED pay dividends? What is the dividend yield for CONMED?: CONMED declared a quarterly dividend on Thursday, August 10th. Stockholders of record on Friday, September 15th will be paid a dividend of $0.20 per share on Thursday, October 5th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.73%. The ex-dividend date is Thursday, September 14th.
Read our dividend analysis for CNMD.
Is CONMED a good dividend stock?: CONMED (NYSE:CNMD) pays an annual dividend of $0.80 per share and currently has a dividend yield of 0.75%. The dividend payout ratio is 43.24%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CNMD will have a dividend payout ratio of 18.10% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for CNMD.
What ETFs hold CONMED's stock?: ETFs with the largest weight of CONMED (NYSE:CNMD) stock in their portfolio include Small Cap US Equity Select ETF (RNSC), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Equipment ETF (XHE), Xtrackers S&P SmallCap 600 ESG ETF (SMLE), SPDR S&P SmallCap 600 ESG ETF (ESIX), SPDR S&P 600 Small Cap ETF (SLY), Vanguard S&P Small-Cap 600 Value ETF (VIOV) and Vanguard S&P Small-Cap 600 ETF (VIOO).
What guidance has CONMED issued on next quarter's earnings?: CONMED issued an update on its FY23 earnings guidance on Wednesday, October, 25th. The company provided EPS guidance of $3.45-3.55 for the period, compared to the consensus EPS estimate of $3.48. The company issued revenue guidance of $1.24-1.26 billion, compared to the consensus revenue estimate of $1.25 billion.
Who are CONMED's major shareholders?: CONMED's stock is owned by a variety of retail and institutional investors. Top institutional investors include Earnest Partners LLC (7.37%), Loomis Sayles & Co. L P (2.57%), Principal Financial Group Inc. (1.99%), Bank of New York Mellon Corp (1.39%), Jennison Associates LLC (1.19%) and Northern Trust Corp (1.10%). Insiders that own company stock include Brian Concannon, Curt R Hartman, Daniel S Jonas, John D Ferrell, Johonna Marie Pelletier, Peter K Shagory, Stanley W Peters III, Todd W Garner and Todd W Garner.
View institutional ownership trends.
How do I buy shares of CONMED?: Shares of CNMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:CNMD) was last updated on 12/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

CONMED Stock Price, News & Analysis (NYSE:CNMD)

CONMED MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About CONMED Stock (NYSE:CNMD)

CNMD Stock Price History

CNMD Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CNMD Stock Analysis - Frequently Asked Questions

Overall MarketRank^™